GlobeNewswire Inc | Sep 30, 2020 07:05AM EDT

September 30, 2020

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Matt Kapusta, chief executive officer at uniQure, Maria Cantor, chief communications officer, and Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in October:

-- SVB LeerinkCybeRx Series: Rare & Genetics, October 1, 2020 Members of uniQures management team will participate in virtual one-on-one investor meetings in the afternoon on Thursday, October 1, 2020. -- Jefferies Virtual Gene Therapy/Editing Summit, October1 2, 2020 A fireside chat withresearch analyst Suji Jeong, Ph.D. will take place on Friday, October 2, 2020 from 9:00 9:25 a.m. ET. The live webcast of the chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event. Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the morning on Friday, October 2, 2020. -- Chardan Virtual 4th Annual Genetic Medicines Conference, October 5 6, 2020 A fireside chat withresearch analyst Gbola Amusa will take place on Tuesday, October 6, 2020 from 1:00 1:25 p.m. ET. The live webcast of the chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event. Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the afternoon on Tuesday, October 6, 2020.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.www.uniQure.com

uniQure Contacts: FOR INVESTORS: FOR MEDIA: Maria E. Cantor Chiara Russo Tom MaloneDirect: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com